Advertisement


Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Advertisement